PTHLH and Hypercalcemia: Up to 30% of cancer patients experience hypercalcemia, which is a common complication [1] usually caused by parathyroid hormone-related protein (PTHrP)-induced humoral hypercalcemia of malignancy (HHM), local osteolytic hypercalcemia (LOH) associated with bone metastasis, or both.